Medigene (MDG1.F)

Executive Summary

Medigene is a German biotechnology company focused on developing T-cell receptor (TCR)-modified T-cell therapies for solid tumors. Its core platform enables the discovery of high-affinity TCRs targeting cancer-specific antigens, including KRAS mutations. The lead candidate, MDG1015, is an autologous TCR-T cell therapy targeting KRAS G12V, a common driver mutation in pancreatic, colorectal, and lung cancers. The company has completed preclinical development and initiated a Phase I trial in solid tumors. Medigene also leverages its dendritic cell vaccine expertise to potentially combine therapies. With a lean structure and partnerships (e.g., with BioNTech in the past), it aims to advance its pipeline through clinical proof-of-concept. Financially, Medigene is funded via existing cash reserves and potential licensing deals, though it remains early stage and cash burn is a key risk. The company trades on the Frankfurt Stock Exchange (MDG1.F) with a modest market cap, reflecting its position as a high-risk, high-reward investment in the immuno-oncology space. Upcoming data from the Phase I trial and potential partnership announcements are critical value inflection points.

Upcoming Catalysts (preview)

• H2 2026Phase I interim data for MDG1015 (KRAS G12V TCR-T)40% success
• Q4 2026Licensing or partnership deal for TCR discovery platform30% success
• H1 2027IND filing for next-generation TCR-T candidate (e.g., targeting p53 mutant)50% success